AUSTRALIANS with the rare, incurable blood cancer mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) now have access to a new treatment, Ledaga (chlormethine gel), launched today under the PBS.
The new, affordable therapy for MF-CTCL is available in Australia, thanks to a collaboration between Arrotex Pharmaceuticals and Juniper Biologics.
Ledaga can help slow cancer progression, offering relief from symptoms like chronic itching and skin discomfort.
Epworth Healthcare's Prof Miles Prince, a leading haematologist, describes Ledaga as "life-changing" for his patients.
"Patients suffer from pain, constant itch, and the cosmetic impact of this disease," explained Prince.
Marketing Director at Juniper Biologics, Caroline Guerbet, highlights this partnership as a vital step forward for patients.
"The listing gives hope to Australians with this lifelong, painful disease," she said.
The Chief Commercial Officer of Arrotex, Hayley Tamborini, said that taking on complex challenges is in Arrotex's DNA.
"We are focused on ensuring timely, sustainable, and affordable access to world-class treatments, such as bringing Ledaga to Australia to help people with MF access the medicines they need," Tamborini commented.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 24
